← Companies
Sponsor / Institution
Oregon Health and Science University
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
3
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
3
0 open data checks
Company / Institution Links
0 / 3
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
23
Completion Signal
0
Programs by Stage
Phase 12
Phase 21
Trial / Program Status
Active1
Completed1
Discontinued1
Modality Mix
Small Molecule2
Steroid/Anti-inflammatory1
Indication Coverage
Hearing Loss2
Aminoglycoside-Induced Hearing Loss1
Ototoxicity1
Sensorineural Hearing Loss1
Sudden Sensorineural Hearing Loss1
Tinnitus1
Program Types
Therapeutic3
Population Tags
adult3
amikacin1
ntm1
ototoxicity1
sensorineural1
study-level1
sudden-hearing-loss1
tinnitus1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
3 checked · 0 open checksOHSU/Oricula ORC-13661 amikacin otoprotection study
Details checked
Small MoleculePhase 2Active
Oral ORC-13661 small molecule evaluated in a randomized Phase 2 dose-ranging trial to prevent or mitigate IV amikacin-associated ototoxic hearing loss in adults with nontuberculous mycobacterial disease.
Data checks: investigator-led-study, industry-collaborator-involved
OHSU Acamprosate Tinnitus Study
Details checked
Small MoleculePhase 1Completed
Historical Phase 1 academic trial evaluating oral acamprosate/Campral versus placebo in tinnitus.
Data checks: institution-led-study, registry-only-evidence
Fludrocortisone Sudden Sensorineural Hearing Loss Study
Details checked
Steroid/Anti-inflammatoryPhase 1Discontinued
Terminated academic early Phase 1 study of oral mineralocorticoid therapy for sudden sensorineural hearing loss after incomplete recovery with standard glucocorticoid treatment.
Data checks: institution-led-study, registry-verified-study